Skip to main content

Table 5 OS and PFS (ITP group)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

  Median OS (months) Median PFS (months)
Protein Expression Low High P-value Low High P-value
 ERCC1 21.4 10.5 0.049 8.2 6 0.558
 COX2 17.7 10.5 0.363 7.9 6 0.895
 Tubulin B3 11.9 16.4 0.529 8.2 7.9 0.74
 CD4 11.9 25.5 0.397 6.6 10.1 0.113
 CD8 11.9 5.4 0.476 7.9 1.2 0.707
SNPs         
 MDR1 C3435T CC TT CT P-value CC TT CT P-value
  3.4 11.9 11.7 0.467 1.8 8.8 8.1 0.484
 MDR1 G2677 T GG TT GT   GG TT GT  
  11.9 2.9 21.9 0.647 6.5 2.9 8.6 0.494
 ERCC1C8092A AA CC CA   AA CC CA  
  25.2 11.9 11.9 0.664 10.2 7.9 6.5 0.702
 ERCC1 N118 N CC TT CT   CC TT CT  
  11.6 21.6 5.6 0.401 8.2 10.1 3.6 0.003